What is lapatinib 250mg Herduo Tablet used for?
lapatinib 250mg Herduo Tablet is used with capecitabine (Xeloda) to treat a certain type of advanced breast cancer in people who have already been treated with other chemotherapy medications.
What is the mechanism of action of lapatinib 250mg Herduo Tablet in breast cancer?
Tykerb (lapatinib) is a HER2 inhibitor that is used to treat cancer. Tykerb inhibits some proteins that can induce uncontrolled cell proliferation in HER2-positive breast tumors.
What is lapatinib 250mg Herduo Tablet oral and how does it work?
lapatinib 250mg Herduo Tablet is a drug that is used to treat a certain form of breast cancer (HER2-positive). It works by slowing or preventing cancer cell proliferation.
What is the dosage of lapatinib?
In a recurring 21-day cycle, the recommended dose of TYKERB is 1,250 mg given orally once daily on Days 1-21 in combination with capecitabine 2,000 mg/m2/day (provided orally in two doses roughly 12 hours apart) on Days 1-14. At least one hour before or after a meal, TYKERB should be consumed.
Who is the manufacturer of lapatinib?
The medicine is marketed by GlaxoSmithKline (GSK) under the brand names Tykerb (primarily in the United States) and Tyverb (mainly in Europe) (mostly in Europe and Russia).
What tests are performed prior to the administration of lapatinib?
Before starting treatment, liver function tests (transaminases, bilirubin, and alkaline phosphatase) should be checked, as well as every 4 to 6 weeks during treatment and as clinically required.
Is lapatinib a monoclonal antibody or a polyclonal antibody?
Lapatinib, unlike big monoclonal antibodies that target the Her2 pathway, may pass the blood-brain barrier and has been shown to be effective in individuals with brain metastases.
When did the FDA approve lapatinib?
On March 13, 2007, the United States Food and Drug Administration approved lapatinib (Tykerb tablets; GlaxoSmithKline, Philadelphia), an oral, small molecule dual tyrosine kinase inhibitor of ErbB-2 and ErbB-1, for use in combination with capecitabine for the treatment of patients with human epidermal growth factor receptor (HER2) positive cancers. Read more